Xalkori is expected to exceed KRW 10 billion in the amount of claims for the first time of the year

The Pfizer Korea’s lung cancer treatment ‘Xalkori Cap(crizotinib)’ has been launched with the insurance benefit on the last 1^st. It is expected that it will exceed KRW 14.5 billion in the first year’s claim amount due to its high cost.

According to the Ministry of Health and Welfare on the 5^th, each Xalkori Cap 200mg and 250mg was newly registered in the pharmaceutical health insurance list by...